Zhangzhou Pientzehuang Pharmaceutical: 2020 annual net profit up 21.27% YoY to about 1.667 billion yuan

NBD AI Bulletin - Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (the Company, SH 600436, closing price: 283.5 yuan) released preliminary earnings estimate on January 19. Operating revenue for 2020 is about 6.507 billion yuan, an increase of 13.72% from a year ago. Net profit attributable to shareholders of the listed company is about 1.667 billion yuan, an increase of 21.27% from the previous year. Basic earnings per share is 2.76 yuan, up 21.05% year over year.

The change in performance is mainly due to strong growth in operating profit driven by increased sales of the Company's Pientzehuang series products and its majority-owned subsidiary Fujian Pientzehuang Cosmetics Co Ltd.

According to the semi-annual report of 2020, Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. mainly engages in pharmaceutical businesses, pharmaceutical-making, pharmaceutical logistics, cosmetics and skincare products, and food sales, accounting for 85.59%, 42.98%, 42.61%, 13.94%, and 0.2% of its revenue respectively.

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.'s chairman is Liu Jianshun, male, 58 years old, senior economist. The Company's general manager is Huang Jinming, male, 55 years old, MBA holder, senior economist, senior engineer, practicing pharmacist.

Tips on "Stock Trends":

1. The number of shares held by northbound investors decreased by 1.3338 million in the past 30 days, accounting for 0.22% of the Company's circulating shares. 

2. There was no institutional research on the Company in the past 30 days.  

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.